Treatment Of Idiopathic Pulmonary Fibrosis With N-acetylcysteine、Roxithromycin Combined With Glucocorticoids

Background The treatment of Idiopathic Pulmonary Fibrosis(IPF) was always a difficult problem. Glucocorticoid was representative drug in traditional treatment; In recent years, with new treatment therapy have researched, Antioxidant represented by N-acetylcysteine(NAC); Anti fibrosis treatment of colchicine and D-penicillamine, and pirfenidone as representative; Further more; molecular targeted drug therapy:such as epidermal growth factor (EGF) receptor antagonist Imatinib, Endothelin receptor antagonist(ERAs) bosentan, egg. Despite drug therapy and medical technology do having rapid progress, the prognosis of IPF was still not ideal. To explore the effective treatment of IPF was important. Glucocorticoid combined with N-acetylcysteine and roxithromycin were adopted in this study, so as to observe its efficacy and further explore its mechanism.Objectives N-acetylcysten、Roxithromycin combined with Glucocorticoids had been used to cure IPF at the same time,to observing the efficacy of these drugs.Methods Patients (n=65) who were diagnosed as IPF were selected, and divided into the treatment group (n=35)and the control group(n=30) randomly.The Patients in the treatment group were cured with N-acetylcysteine Roxithromycin combined with Glucocorticoids. The Patients in the control group were cured with Glucocorticoids only. The mean follow-up time was6months.Observe the improvement degree of FVC%pred、VC%pred、 PO2、exercise tolerance test、Brog、CAT and HRCT.Results Brog、FVC%pred%and VC%pred of the treatment group were improved significantly compared with the control group (P<0.05)。Ground-glass opacities in HRCT more reduced in the treatment group than in the control group(P<0.05). The date of COPD Assessment Test in the treatment group was higher than in the control group(P< 0.05).Conclusions The treatment with medicine of N-acetylcysteine、Roxithromycin and Glucocorticoids can improve the living quality、pulmonary function and symptom of dyspnea. The researched therapy could change the ending of acute exudative inflammation, that was ground-glass opacity on chest HRCT. But the treatment plan needs further research for the effect of long-term survival.